Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
BioVaxys converted $25K in debt plus interest into 148,468 shares and granted 550K stock options to insiders.
BioVaxys Technology Corp. converted $25,000 in convertible debentures plus $239.73 in accrued interest into 148,468 common shares at $0.17 per share after a holder’s notice.
The company also granted 550,000 stock options to insiders and key personnel, exercisable at $0.25 per share until October 20, 2030, with gradual vesting.
The transactions were exempt from certain Canadian regulations due to limited insider involvement.
The firm, based in British Columbia, develops immunotherapies for cancer, infectious diseases, and allergies using its DPX™ and HapTenix© platforms.
Its lead candidate, maveropepimut-S, is in Phase IIb trials for advanced lymphoma and ovarian cancer, demonstrating safety and immune response.
Other pipeline projects include dual-targeted therapies, peanut allergy treatments, and personalized cancer vaccines.
All securities are subject to regulatory approval and are not registered for sale in the U.S.
BioVaxys convirtió $ 25K en deuda más intereses en 148,468 acciones y otorgó 550K opciones de acciones a los privilegiados.